| TRAIL重组蛋白联合扶正抑瘤方诱导HepG2肝癌细胞凋亡的研究 |
| |
| 引用本文： | 冯全林,曹晓蕾.TRAIL重组蛋白联合扶正抑瘤方诱导HepG2肝癌细胞凋亡的研究[J].中国交通医学杂志,2009,23(6):602-604. |
| |
| 作者姓名： | 冯全林 曹晓蕾 |
| |
| 作者单位： | 冯全林(南京中医药大学附属昆山中医院普外科,江苏,215300);曹晓蕾(南通大学医学院) |
| |
| 摘 要： | 目的:研究重组人可溶性TRAIL蛋白联合扶正抑瘤方诱导肝癌细胞HepG2凋亡的作用和意义。方法:HepG2细胞经重组人可溶性TRAIL蛋白及联合扶正抑瘤方处理后,以MTT法测定细胞存活率、流式细胞术检测细胞凋亡指数。结果:扶正抑瘤方对促进TRAIL蛋白诱导的HepG2的凋亡作用存在较好的量效和时效关系,其最佳作用剂量和最佳作用时间分别为105mg/ml和24小时。结论:扶正抑瘤方能加强TRAIL诱导HepG2肝癌细胞凋亡作用。
|
| 关 键 词： | 肝癌 扶正抑瘤方 肝瘤坏死因子相关凋亡诱导配体 细胞凋亡 |
The study of HepG2 hepatic carcinoma cell's apoptosis induced by the recombined TRAIL and Fuzhengyiliufang |
| |
| Abstract: | Objective: To study the recombined solubilitied human TRAIL and Fuzhengyiliufang in the HepG2 hepatic carcinoma cell’s apoptosis. Methods: The HepG2 cells with recombined solubilitied human TRAIL and Fuzhengyiliufang were treated, and then the cell survival rate was detected by MTT, and the cell apoptotic index, by flow cytometry. Results: Fuzhengyiliufang could promoted TRAIL to induce cells apoptosis in the dose-dependent and time-dependent way, and at the 105mg/ml the and 24 hours, the effects reached the high level. Conclusion: Fuzhengyiliufang could promote the HepG2 cells apoptosis induced by TRAIL. |
| |
| Keywords: | hepatic carcinoma Fuzhengyiliufang TRAIL apoptosis |
| 本文献已被 维普 万方数据 等数据库收录！ |
